Hemispherx BioPharma Company Profile (NYSE:HEB)

About Hemispherx BioPharma

Hemispherx BioPharma logoHemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: HEB
  • CUSIP:
Key Metrics:
  • Previous Close: $1.29
  • 50 Day Moving Average: $1.64
  • 200 Day Moving Average: $1.57
  • 52-Week Range: $0.72 - $2.64
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $26.76M
  • Outstanding Shares: 20,744,000
Additional Links:
Companies Related to Hemispherx BioPharma:

Analyst Ratings

Consensus Ratings for Hemispherx BioPharma (NYSE:HEB) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Hemispherx BioPharma (NYSE:HEB)
Show:
DateFirmActionRatingPrice TargetDetails
4/2/2015Midtown PartnersInitiated CoverageStrong-Buy$1.45View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Hemispherx BioPharma (NYSE:HEB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2015        
8/15/2016Q216($0.01)ViewN/AView Earnings Details
5/16/2016Q116($0.01)$40.99 millionViewN/AView Earnings Details
8/13/2015Q2($0.02)ViewN/AView Earnings Details
5/13/2015Q1 15($0.02)ViewN/AView Earnings Details
8/9/2013Q2 2013($0.03)ViewN/AView Earnings Details
11/5/2012Q312($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Hemispherx BioPharma (NYSE:HEB)
Current Year EPS Consensus Estimate: $0.00 EPS
Next Year EPS Consensus Estimate: $-0.03 EPS

Dividends

Dividend History for Hemispherx BioPharma (NYSE:HEB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Hemispherx BioPharma (NYSE:HEB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/8/2016Thomas K EquelsCEOBuy48,000$0.12$5,760.00View SEC Filing  
7/1/2016Thomas K EquelsCEOBuy171,000$0.12$20,520.00View SEC Filing  
3/18/2016Thomas K EquelsCEOBuy30,000$0.13$3,900.00View SEC Filing  
3/11/2016Thomas K EquelsCEOBuy40,000$0.16$6,400.00View SEC Filing  
3/10/2016Thomas K EquelsCEOBuy30,000$0.16$4,800.00View SEC Filing  
8/20/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/18/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/17/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/14/2015Thomas K EquelsCFOBuy79,104$0.18$14,238.72View SEC Filing  
4/28/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/27/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/21/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/20/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/17/2015William A CarterCEOBuy73,681$0.23$16,946.63View SEC Filing  
4/16/2015William A CarterCEOBuy26,319$0.23$6,053.37View SEC Filing  
4/15/2015Thomas K EquelsCFOBuy100,000$0.23$23,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Hemispherx BioPharma (NYSE:HEB)
DateHeadline
News IconPenny Stock Investors are Growing Curious About Hemispherx Biopharma, Inc. (:HEB) - Duncan Research (NYSE:HEB)
www.duncanindependent.com - September 28 at 10:15 AM
smarteranalyst.com logoStock Update (NYSEMKT:HEB): Hemispherx BioPharma, Inc Announces Granting of Final Settlement of Derivative and ... - Smarter Analyst (NYSE:HEB)
www.smarteranalyst.com - September 24 at 5:01 PM
4-traders.com logoHemispherx Biopharma : Announces Granting of Final Settlement of Derivative and Class Action Case (NYSE:HEB)
www.4-traders.com - September 23 at 10:22 AM
finance.yahoo.com logo8:38 am Hemispherx Biopharma announces final settement of the derivative and class action case captioned Kastis, et al. v. Carter, et al. (NYSE:HEB)
finance.yahoo.com - September 22 at 5:26 PM
publicnow.com logoHemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case (NYSE:HEB)
www.publicnow.com - September 22 at 5:26 PM
globenewswire.com logoHemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards - GlobeNewswire (press release) (NYSE:HEB)
globenewswire.com - September 21 at 9:37 AM
News IconPenny Stock Investors Take an Interest in Hemispherx Biopharma, Inc. (:HEB) - Duncan Research (NYSE:HEB)
www.duncanindependent.com - September 21 at 9:37 AM
4-traders.com logoHemispherx Biopharma : Regains Compliance with NYSE MKT Continued Listing Standards (NYSE:HEB)
www.4-traders.com - September 20 at 10:30 AM
News IconHemispherx Regains Compliance With NYSE MKT Continued Listing Standards (NYSE:HEB)
www.biospace.com - September 19 at 5:28 PM
publicnow.com logoHemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards (NYSE:HEB)
www.publicnow.com - September 19 at 9:58 AM
News IconShort Interest in Hemispherx BioPharma, Inc (HEB) Drops By 59.9% - National Daily Press (NYSE:HEB)
www.nationaldailypress.com - September 16 at 9:18 AM
News IconMarket Movers - LeMaitre Vascular, Inc. (NASDAQ:LMAT) , Hemispherx BioPharma, Inc. (NYSEMKT:HEB) - Wall Street Times (press release) (NYSE:HEB)
www.wallstreetnews24.com - September 12 at 10:08 AM
bizjournals.com logoPhiladelphia biotech firm expecting $5M from stock sale (NYSE:HEB)
www.bizjournals.com - September 6 at 5:24 PM
finance.yahoo.com logoHemispherx Biopharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference (NYSE:HEB)
finance.yahoo.com - September 6 at 10:08 AM
News IconWith Hemispherx BioPharma, Inc (NYSEMKT:HEB), It All Comes Down To US Ampligen (NYSE:HEB)
streetregister.com - September 2 at 5:22 PM
News IconNews review of 2 biotech stocks: Hemispherx Biopharma, Inc ... - The Voice Registrar (NYSE:HEB)
voiceregistrar.com - September 2 at 10:15 AM
News IconWith Hemispherx BioPharma, Inc (NYSEMKT:HEB), It All Comes Down To US Ampligen - Street Register (NYSE:HEB)
streetregister.com - September 2 at 10:15 AM
globenewswire.com logoHemispherx Biopharma, Inc. Announces $5 Million Registered Direct Offering - GlobeNewswire (press release) (NYSE:HEB)
globenewswire.com - September 2 at 10:15 AM
News IconStock Gapping to the Downside Pre-Market: Hemispherx Biopharma ... - Post News (NYSE:HEB)
www.kentuckypostnews.com - September 1 at 8:21 AM
News IconStock Down in Trading Session: Hemispherx Biopharma, Inc. (:HEB) - Post News (NYSE:HEB)
www.kentuckypostnews.com - September 1 at 8:21 AM
benzinga.com logo12 Biggest Mid-Day Losers For Wednesday - Benzinga - Benzinga (NYSE:HEB)
www.benzinga.com - September 1 at 8:21 AM
smarteranalyst.com logoStock Update (NYSEMKT:HEB): Hemispherx BioPharma, Inc Announces $5 Million Registered Direct Offering - Smarter Analyst (NYSE:HEB)
www.smarteranalyst.com - September 1 at 8:21 AM
publicnow.com logoHemispherx Biopharma, Inc. Announces $5 Million Registered Direct Offering (NYSE:HEB)
www.publicnow.com - August 31 at 10:09 AM
finance.yahoo.com logoHemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA (NYSE:HEB)
finance.yahoo.com - August 29 at 5:18 PM
publicnow.com logoHemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI's 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA (NYSE:HEB)
www.publicnow.com - August 29 at 5:18 PM
News IconHemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through… (NYSE:HEB)
forextv.com - August 29 at 9:57 AM
biz.yahoo.com logoSplits Calendar: Hemispherx Biopharma splits before market open today (1:12 ratio) (NYSE:HEB)
biz.yahoo.com - August 29 at 9:57 AM
News IconFirst Product Approved for ME/CFS Indication Anywhere in the World (NYSE:HEB)
www.investorideas.com - August 26 at 5:15 PM
rttnews.com logoHemispherx Announces Approval For Commercial Sale Of Rintatolimod In Argentine (NYSE:HEB)
www.rttnews.com - August 25 at 10:25 AM
4-traders.com logoHemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod... (NYSE:HEB)
www.4-traders.com - August 25 at 10:25 AM
News IconVolatile Movements - Cisco Systems (NASDAQ:CSCO), Hemispherx BioPharma (NYSEMKT:HEB) - Money News (press release) (NYSE:HEB)
www.newsismoney.com - August 24 at 5:16 PM
News IconTime To Put On The Watch List? - Hemispherx Biopharma, Inc. (NYSEMKT:HEB), Keryx Biopharmaceuticals Inc ... - The Voice Registrar (NYSE:HEB)
voiceregistrar.com - August 24 at 5:16 PM
News IconHemispherx Biopharma, Inc.'s (HEB): See the most Active Stock of Market - Hot Stocks Point (NYSE:HEB)
www.hotstockspoint.com - August 24 at 8:31 AM
smarteranalyst.com logoStock Update (NYSEMKT:HEB): Hemispherx BioPharma, Inc Announces Approval of Rintatolimod in the Argentine ... - Smarter Analyst (NYSE:HEB)
www.smarteranalyst.com - August 24 at 8:31 AM
streetinsider.com logoHemispherx Biopharma (HEB) Receives ANMAT Approval for Commercial Sale of Rintatolimod in Argentine Republic (NYSE:HEB)
www.streetinsider.com - August 23 at 5:35 PM
nasdaq.com logoHemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U. (NYSE:HEB)
www.nasdaq.com - August 23 at 9:47 AM
publicnow.com logoHemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic (NYSE:HEB)
www.publicnow.com - August 23 at 9:47 AM
biz.yahoo.com logoHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NYSE:HEB)
biz.yahoo.com - August 20 at 9:36 AM
globenewswire.com logoHemispherx Biopharma Forms Scientific Advisory Board to Provide Additional Scientific and Pharmaceutical Expertise (NYSE:HEB)
globenewswire.com - August 19 at 5:22 PM
4-traders.com logoHemispherx Biopharma : Announces 1-for-12 Reverse Stock Split (NYSE:HEB)
www.4-traders.com - August 18 at 5:24 PM
bizjournals.com logoHemispherx stockholders approve reverse stock split (NYSE:HEB)
www.bizjournals.com - August 18 at 5:24 PM
News IconActive biotech company shares in the news: Hemispherx Biopharma ... - The Voice Registrar (NYSE:HEB)
voiceregistrar.com - August 18 at 8:25 AM
publicnow.com logoHemispherx Biopharma Announces 1-for-12 Reverse Stock Split (NYSE:HEB)
www.publicnow.com - August 17 at 5:38 PM
biz.yahoo.com logoHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events (NYSE:HEB)
biz.yahoo.com - August 17 at 5:38 PM
rttnews.com logoEARNINGS SUMMARY: Details of Hemispherx Biopharma, Inc. Q2 Earnings Report (NYSE:HEB)
www.rttnews.com - August 16 at 8:46 AM
finance.yahoo.com logoHemispherx Biopharma Conducts an Interview with The Wall Street Transcript (NYSE:HEB)
in.finance.yahoo.com - August 15 at 5:36 PM
biz.yahoo.com logoHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, (NYSE:HEB)
biz.yahoo.com - August 15 at 5:36 PM
publicnow.com logoHemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2016 (NYSE:HEB)
www.publicnow.com - August 15 at 5:36 PM
News IconAnalyst Research and Ratings: Hemispherx Biopharma, Inc. (NYSEMKT:HEB), Twitter, Inc. (NYSE:TWTR) - TWN (NYSE:HEB)
thewellesleysnews.com - August 7 at 5:10 PM
News IconBiotech Stocks To Put On Your Watch List: Hemispherx Biopharma, Inc. (NYSEMKT:HEB), Sangamo Biosciences Inc ... - The Voice Registrar (NYSE:HEB)
voiceregistrar.com - August 5 at 5:31 PM

Social

Hemispherx BioPharma (NYSE:HEB) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff